Abeona Therapeutics: Maintaining 'Buy' on ZEVASKYN Launch Potential for RDEB

Abeona Therapeutics maintains a "Buy" rating on its ZEVASKYN launch potential for RDEB, with an expected launch in the second half of 2023. The company's lead product, ZEVASKYN, has shown positive results in treating recessive dystrophic epidermolysis bullosa (RDEB). The potential launch is expected to generate significant revenue for the company.